Synergy and order effects of antibiotics and phages in killing pseudomonas aeruginosa biofilms

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Chaudhry, Waqas Nasir ^a,b   Concepcion Acevedo, Jeniffer ^b   Park, Taehyun ^c   Andleeb, Saadia ^a   Bull, James J ^c   Levin, Bruce R ^b  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

^b EMORY UNIVERSITY   (United States)

^c UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BACTERIUM MUTANT; BIOFILM; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; EPITHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; POPULATION DENSITY; PSEUDOMONAS AERUGINOSA; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; PHYSIOLOGY; PSEUDOMONAS PHAGE; VIROLOGY;

ANTI-BACTERIAL AGENTS; BIOFILMS; CELL LINE; EPITHELIAL CELLS; HUMANS; MODELS, BIOLOGICAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PHAGES;

EID: 85009270157     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168615     Document Type: Article

References (48)

1. Clarke T. Drug companies snub antibiotics as pipeline threatens to run dry. Nature. 2003; 425 (6955):225-.
2. Hancock RE. The end of an era? Nature Reviews Drug Discovery. 2007; 6(1):28-.
3. Hawkey PM, Jones AM. The changing epidemiology of resistance. Journal of Antimicrobial Chemotherapy. 2009; 64(suppl 1):i3-i10.
4. Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014; 20(7):1170-5. doi: 10.3201/eid2007. 121004 PMID: 24959688
5. Mc Gann P, Snesrud E, Maybank R, Corey B, Ong AC, Clifford R, et al. Escherichia coli Harboring mcr-1 and blaCTX-M on a Novel Inc F Plasmid: First report of mcr-1 in the USA. Antimicrobial agents and chemotherapy. 2016.
6. Sanchez-Romero MA, Casadesus J. Contribution of phenotypic heterogeneity to adaptive antibiotic resistance. Proceedings of the National Academy of Sciences. 2014; 111(1):355-60.
7. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: from the natural environment to infectious diseases. Nature reviews microbiology. 2004; 2(2):95-108. doi: 10.1038/nrmicro821 PMID: 15040259
8. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science. 1999; 284(5418):1318-22. PMID: 10334980
9. Davies D. Understanding biofilm resistance to antibacterial agents. Nature Reviews Drug Discovery. 2003; 2(2):114-22. doi: 10.1038/nrd1008 PMID: 12563302
10. Kirby AE, Garner K, Levin BR. The relative contributions of physical structure and cell density to the anti-biotic susceptibility of bacteria in biofilms. Antimicrobial agents and chemotherapy. 2012; 56(6):2967-75. doi: 10.1128/AAC.06480-11 PMID: 22450987
11. Bull J, Levin BR, De Rouin T, Walker N, Bloch CA. Dynamics of success and failure in phage and antibiotic therapy in experimental infections. BMC microbiology. 2002; 2(1):1.
12. Haq IU, Chaudhry WN, Akhtar MN, Andleeb S, Qadri I. Bacteriophages and their implications on future biotechnology: a review. Virology journal. 2012; 9(1):1.
13. Knezevic P, Curcin S, Aleksic V, Petrusic M, Vlaski L. Phage-antibiotic synergism: a possible approach to combatting Pseudomonas aeruginosa. Research in microbiology. 2013; 164(1):55-60. doi: 10.1016/j.resmic.2012.08.008 PMID: 23000091
14. Torres-Barcelo C, Arias-Sanchez FI, Vasse M, Ramsayer J, Kaltz O, Hochberg ME. A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS one. 2014; 9(9):e106628. doi: 10.1371/journal.pone.0106628 PMID: 25259735
15. Torres-Barcelo C, Hochberg ME. Evolutionary rationale for phages as complements of antibiotics. Trends in microbiology. 2016; 24(4):249-56. doi: 10.1016/j.tim.2015.12.011 PMID: 26786863
16. Lu TK, Collins JJ. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy. Proc Natl Acad Sci USA. 2009; 106(12):4629-34. doi: 10.1073/pnas.0800442106 PMID: 19255432
17. Abedon ST. Bacteriophages and biofilms: Nova Science Publishers, Inc.; 2011.
18. Harper DR, Parracho HM, Walker J, Sharp R, Hughes G, Werthen M, et al. Bacteriophages and biofilms. Antibiotics. 2014; 3(3):270-84.
19. Abedon ST. Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages. Pharmaceuticals. 2015; 8(3):525-58. doi: 10.3390/ph8030525 PMID: 26371010
20. Hoiby N, Ciofu O, Bjarnsholt T. Pseudomonas aeruginosa biofilms in cystic fibrosis. Future microbiology. 2010; 5(11):1663-74. doi: 10.2217/fmb.10.125 PMID: 21133688
21. Gonzalez MR, Fleuchot B, Lauciello L, Jafari P, Applegate LA, Raffoul W, et al. Effect of Human Burn Wound Exudate on Pseudomonas aeruginosa Virulence. mSphere. 2016; 1(2):e00111-15. doi: 10. 1128/mSphere.00111-15 PMID: 27303724
22. Migiyama Y, Yanagihara K, Kaku N, Harada Y, Yamada K, Nagaoka K, et al. Pseudomonas aeruginosa bacteremia among immunocompetent and immunocompromised patients: relation to initial antibiotic therapy and survival. Japanese journal of infectious diseases. 2015;(0).
23. Chaudhry WN, Badar R, Jamal M, Jeong J, Zafar J, Andleeb S. Clinico microbiological study and antibiotic resistance profile of mecA and ESBL gene prevalence in patients with diabetic foot infections. Experimental and therapeutic medicine. 2016; 11(3):1031-8. doi: 10.3892/etm.2016.2996 PMID: 26998033
24. Livermore DM. Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clinical infectious diseases. 2002; 34(5):634-40. doi: 10.1086/338782 PMID: 11823954
25. Weinbauer MG. Ecology of prokaryotic viruses. FEMS microbiology reviews. 2004; 28(2):127-81. doi: 10.1016/i.femsre.2003.08.001 PMID: 15109783
26. Breitbart M, Rohwer F. Here a virus, there a virus, everywhere the same virus? Trends in microbiology. 2005; 13(6):278-84. doi: 10.1016/am.2005.04.003 PMID: 15936660
27. Essoh C, Latino L, Midoux C, Blouin Y, Loukou G, Nguetta S-PA, et al. Investigation of a large collection of Pseudomonas aeruginosa bacteriophages collected from a single environmental source in Abidjan, Cote d'Ivoire. PLoS one. 2015; 10(6):e0130548. doi: 10.1371/journal.pone.0130548 PMID: 26115051
28. Alemayehu D, Casey PG, Mc Auliffe O, Guinane CM, Martin JG, Shanahan F, et al. Bacteriophages MR299-2 and NH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio. 2012; 3(2):e00029-12. doi: 10.1128/mBio.00029-12 PMID: 22396480
29. Smith HW, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J Gen Microbiol. 1982; 128(2):307-18. doi: 10.1099/00221287-128-2-307 PMID: 7042903
30. Danis-Wlodarczyk K, Vandenheuvel D, Jang HB, Briers Y, Olszak T, Arabski M, et al. A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections. Scientific Reports. 2016; 6.
31. Chan BK, Sistrom M, Wertz JE, Kortright KE, Narayan D, Turner PE. Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci Rep. 2016; 6:26717. doi: 10.1038/srep26717 PMID: 27225966
32. Greco W, Unkelbach H, Poch G, Suhnel J, Kundi M, Bodeker W. Consensus on concepts and terminology for combined-action assessment: the Saariselka agreement. Arch Complex Environ Stud. 1992; 4 (3):65-9.
33. Baeder DY, Yu G, Hoze N, Rolff J, Regoes RR. Antimicrobial combinations: Bliss independence and Loewe additivity derived from mechanistic multi-hit models. Phil Trans R Soc B. 2016; 371 (1695):20150294. doi: 10.1098/rstb.2015.0294 PMID: 27160596
34. Piggott JJ, Townsend CR, Matthaei CD. Reconceptualizing synergism and antagonism among multiple stressors. Ecology and evolution. 2015; 5(7):1538-47. doi: 10.1002/ece3.1465 PMID: 25897392
35. Haas C, Nix DE, Schentag J. In vitro selection of resistant Helicobacter pylori. Antimicrobial agents and chemotherapy. 1990; 34(9):1637-41. PMID: 2285275
36. Garbe J, Wesche A, Bunk B, Kazmierczak M, Selezska K, Rohde C, et al. Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC microbiology. 2010; 10(1):1.
37. Giamarellou H. Prescribing guidelines for severe Pseudomonas infections. Journal of Antimicrobial Chemotherapy. 2002; 49(2):229-33. PMID: 11815561
38. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically; Approved Standard-Ninth Edition.: Clinical and Laborratory Standards Institure; 2013.
39. EUCAST. The European Comittee on Antimicrobail Susceptibility Testing-Clinical Breakpoints 2013. http://www.eucast.org/clinical breakpoints/.
40. Anderson GG, Moreau-Marquis S, Stanton BA, O'Toole GA. In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infection and immunity. 2008; 76(4):1423-33. doi: 10.1128/IAI.01373-07 PMID: 18212077
41. Constantinou A, Voelkel-Meiman K, Sternglanz R, Mc Corquodale M, Mc Corquodale D. Involvement of host DNA gyrase in growth of bacteriophage T5. Journal of virology. 1986; 57(3):875-82. PMID: 2419589
42. Levin BR, Stewart FM, Chao L. Resource-limited growth, competition, and predation: a model and experimental studies with bacteria and bacteriophage. American Naturalist. 1977; 977:3-24.
43. Payne RJ, Jansen VA. Understanding bacteriophage therapy as a density-dependent kinetic process. Journal of Theoretical Biology. 2001; 208(1):37-48. doi: 10.1006/itbi.2000.2198 PMID: 11162051
44. Alonso JC, Sarachu AN, Grau O. DNA gyrase inhibitors block development of Bacillus subtilis bacteriophage SP01. Journal of virology. 1981; 39(3):855-60. PMID: 6270354
45. Hamatake RK, Mukai R, Hayashi M. Role of DNA gyrase subunits in synthesis of bacteriophage phi X174 viral DNA. Proceedings of the National Academy of Sciences. 1981; 78(3):1532-6.
46. Escobar-Paramo P, Gougat-Barbera C, Hochberg ME. Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evolutionary applications. 2012; 5(6):583-92. doi: 10.1111/i.1752-4571.2012.00248.x PMID: 23028399
47. Kirby AE. Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus. PLoS One. 2012; 7(11):e51017. doi: 10.1371/journal.pone.0051017 PMID: 23226451
48. Gupta SK. Non-inferiority clinical trials: Practical issues and current regulatory perspective. Indian J Pharmacol. 2011; 43(4):371-4. doi: 10.4103/0253-7613.83103 PMID: 21844987